ARQT
Arcutis Biotherapeutics, Inc.
NASDAQ · Healthcare · Biotechnology · US
$23.90
+1.01%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 464.0M | 376.1M | 196.5M | 59.6M | 3.7M |
| Cost of Revenue | 41.1M | 36.7M | 19.1M | 5.0M | 754.0K |
| Gross Profit | 422.9M | 339.4M | 177.4M | 54.6M | 2.9M |
| Operating Expenses | |||||
| R&D Expense | 91.0M | 77.1M | 76.4M | 110.6M | 182.4M |
| SG&A Expense | 297.6M | 274.6M | 229.4M | 185.1M | 122.1M |
| General & Admin Expense | 82.1M | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 388.6M | 351.6M | 305.8M | 295.7M | 304.6M |
| Cost and Expenses | 429.7M | 388.3M | 324.9M | 300.7M | 305.3M |
| Operating Income (EBIT) | 34.3M | (12.2M) | (128.4M) | (241.1M) | (301.6M) |
| Non-Operating | |||||
| Interest Income | 4.6M | — | — | — | — |
| Interest Expense | 13.8M | 12.1M | 27.2M | 29.7M | 15.7M |
| Net Interest Income | (9.3M) | (12.1M) | (27.2M) | (29.7M) | (15.7M) |
| Other Non-Op Income/Expense | (5.0M) | (2.7M) | (11.0M) | (17.9M) | (9.8M) |
| Non-Operating Income (excl Interest) | (6.9M) | (9.3M) | (16.2M) | (11.8M) | (5.8M) |
| EBT (Pre-Tax Income) | 29.3M | (15.0M) | (139.4M) | (259.0M) | (311.5M) |
| Income Tax Expense | 779.0K | 1.2M | 647.0K | 3.1M | — |
| Bottom Line | |||||
| Net Income | 28.5M | (16.1M) | (140.0M) | (262.1M) | (311.5M) |
| Earnings from Cont. Ops | 28.5M | (16.1M) | (140.0M) | (262.1M) | (311.5M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 28.5M | (16.1M) | (140.0M) | (262.1M) | (311.5M) |
| Per Share | |||||
| Basic EPS | $0.22 | ($0.13) | ($1.16) | ($3.78) | ($5.66) |
| Diluted EPS | $0.21 | ($0.13) | ($1.16) | ($3.78) | ($5.66) |
| Revenue Per Share | $3.55 | $2.96 | $1.62 | $0.86 | $0.07 |
| Shares | |||||
| Basic Shares Outstanding | 130.5M | 127.2M | 121.0M | 69.3M | 55.0M |
| Diluted Shares Outstanding | 135.9M | 127.2M | 121.0M | 69.3M | 55.0M |
| Profitability Metrics | |||||
| EBITDA | 44.1M | 2.5M | (109.6M) | (227.4M) | (294.6M) |
| D&A | 3.0M | 5.4M | 2.6M | 1.9M | 1.3M |
| EBIT | 41.2M | (2.9M) | (112.2M) | (229.3M) | (295.8M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026